國家衛生研究院 NHRI:Item 3990099045/10929
English  |  正體中文  |  简体中文  |  全文筆數/總筆數 : 12145/12927 (94%)
造訪人次 : 856909      線上人數 : 953
RC Version 6.0 © Powered By DSPACE, MIT. Enhanced by NTU Library IR team.
搜尋範圍 查詢小技巧：
  • 您可在西文檢索詞彙前後加上"雙引號"，以獲取較精準的檢索結果
  • 若欲以作者姓名搜尋，建議至進階搜尋限定作者欄位，可獲得較完整資料
    •  進階搜尋
    主頁 ‧ 登入 ‧ 上傳 ‧ 說明 ‧ 關於NHRI ‧ 管理 到手機版


    請使用永久網址來引用或連結此文件: http://ir.nhri.org.tw/handle/3990099045/10929


    題名: Adsorption of a tumor-associated antigen onto crystalized rapamycin nanoparticles for combined immuno- and antitumor therapy
    作者: Pan, CH;Yen, JY;Hsiao, YJ
    貢獻者: National Institute of Infectious Diseases and Vaccinology
    摘要: Aims: To evaluate rapamycin nanoparticles adsorbed with a tumor antigen (ovalbumin) as a combined vaccine to suppress tumor growth and enhance the immune response. Rapamycin (Sirolimus) is an mTOR inhibitor that suppresses tumor growth, low doses of which have been reported to enhance the immune response. Methods: Rapamycin was crystalized into nanoparticles and analyzed using a particle analyzer. The protein binding capacity of the rapamycin particles, and their ability to inhibit cell proliferation were analyzed. The immune activation of the rapamycin particles was also tested both in vitro and in vivo. Results: Rapamycin nanoparticles had a diameter around 500 nm, a zeta potential of + 9 mV, and a protein binding capacity of 8 l g/mg. The rapamycin nanoparticles had a similar inhibitory effect on Raw264.7 macrophage cells as rapamycin. The mTOR phosphorylation was also reduced in a similar level by either rapamycin nanoparticles or rapamycin. In addition, the expression of CD80 and CD86 was not affected by the rapamycin nanoparticles, and immune responses were elicited by the rapamycin particulate vaccine. Conclusions: The rapamycin particulate tumor vaccine has a potential to induce an immune response to a tumor antigen and inhibit tumor growth.
    日期: 2017-11
    關聯: Basic and Clinical Pharmacology and Toxicology. 2017 Nov;121(Suppl. 5):38.
    Link to: http://dx.doi.org/10.1111/bcpt.12911
    JIF/Ranking 2023: http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcAuth=NHRI&SrcApp=NHRI_IR&KeyISSN=1742-7835&DestApp=IC2JCR
    Cited Times(WOS): https://www.webofscience.com/wos/woscc/full-record/WOS:000417470500105
    顯示於類別:[潘建雄] 會議論文/會議摘要

    文件中的檔案:

    檔案 描述 大小格式瀏覽次數
    ISI000417470500105.pdf41KbAdobe PDF325檢視/開啟


    在NHRI中所有的資料項目都受到原著作權保護.

    TAIR相關文章

    DSpace Software Copyright © 2002-2004  MIT &  Hewlett-Packard  /   Enhanced by   NTU Library IR team Copyright ©   - 回饋